While the 5-year survival rate for localized or regional PCa is nearly 100%, 10–20% of patients will inevitably develop lethal castration-resistant PCa (CRPC) due to promiscuous or overactive AR activity in PCa cells or, conversely, due to PCa cell adaptation to low or no AR accumulation [5,6,7,8]. The gene discussed is AR; the disease is posterior cortical atrophy.